This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Annual Report and Accounts

31 March 2021

Company registration number 02908933 | Charity registration number 1040650

Contents
Charity Information	1
Trustees’ Annual Report	1
Statement Of Directors’ Responsibilities	9
Independent Examiner’s Report	11
Funds Statements:
Statement Of Financial Activities	13
Statement Of Financial Activities - Prior Year Statement	14
Statement Of Total Recognised Gains And Losses	15
Movements In Funds	17
Revenue Funds	18
Income And Expenditure Account	19
Balance Sheet	20

Notes To The Accounts 22

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021

The Trustees present their Report and Accounts for the year ended 31 March 2021, which also comprises the Directors’ Report required by the Companies Act 2006.

The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:

Charity Name

The legal name of the charity is: Bath Institute for Rheumatic Diseases.

The charity is also known by its operating name, BIRD.

The charity’s areas of operation and UK charitable registration.

The charity is registered with the Charity Commission in England & Wales (CCEW) with charity number 1040650.

The charity does not operate in any overseas jurisdictions.

Legal structure of the Charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

Department D1 Wolfson Building, Royal United Hospital Bath BA1 3NG Telephone: 01225 336363 Email Address: BIRD@birdbath.org.uk Web Address: www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in Office on the Date the Report was Approved were:

Dr N Hall Mr C Johns (Chair) Mr J Sherwin Dr A Mackenzie Dr R Sengupta Dr J Pauling Dr W Tillett Ms S Lear Prof N McHugh

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

Objects and Activities of the Charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

In November 2020 the Articles of Association for BIRD were updated, mainly along the lines of the Charity Commission’s model constitution. This was last done in 1994. Nineteen previous trustees were contacted to ensure clarity over the members’ register since part of the update was to provide that the only “members” will be the trustees, so that any change in the trustees automatically updates the changes in the membership. The changes were adopted unanimously and the new Articles were given consent by the Charity Commission.

Response to the Covid 19 pandemic

The country was in lockdown in response to the Covid 19 pandemic by the period starting this report. This had impacted BIRD’s plans considerably. All live events (Patient engagement days and Education seminars for Healthcare Professionals, also the annual fundraising/awareness raising event) were cancelled and the office was closed. Consultant Trustees and other healthcare professionals on BIRD’s committees were pulled into patient care on the wards. Laboratories were closed and opened up only gradually during the year with improved social distancing, causing bottlenecks and delays to projects.

BIRD’s response was to switch all staff to working from home, a pre-existing arrangement for many contractors. Instead of the programme of patient information days across a range of rheumatic disease areas, this was replaced by, initially, a trial of podcast interviews with specialists available to listeners via an online platform, Anchor. To ensure the widest possible reach, these were advertised on Facebook using a specialist agency, as well as promoted to patients via the usual e-newsletter and postal mailings. Following successful results in terms of numbers reached, listening length and qualitative feedback (details below), a programme of podcasts was developed and launched over the year, creating a new library resource for patients on BIRD’s website.

To address the difficulties in conducting research when laboratory access was restricted or patient recruitment suspended, the Research Committee decided to write proactively to all live funded projects to offer support. As a result, many time extensions were granted and five cost extensions, amounting to £23,216.50 to allow the projects to proceed. BIRD has received many plaudits for this support and understanding of the difficulties that researchers faced during the pandemic.

The education programme for consultants, GPs, nurses and physiotherapists was also switched from in-person to online training. While numbers attending increased significantly, pharmaceutical companies were not able to sponsor virtual meetings due to their internal policies, impacting BIRD’s income.

The planned Autumn awareness raising and fundraising event was deferred and other methods of raising awareness implemented instead (see below).

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

A r o

Grants awarded for Research

BIRD funds research projects in rheumatic diseases which:

£23,216.50 to cover cost extensions of live projects impacted by the pandemic
£24,107 towards Dr Sarah Tansley’s National Institute for Health Research Clinical Lectureship, each year for three years

Grant programme evaluation report

Help to promote and advance medical knowledge
Improve treatments for patients
Encourage collaboration between clinicians and research scientists
Supports the next generation of researchers into bone and joint diseases

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £10,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

In total, £78,823.50 was awarded:

£11,500 to Dr Jennifer Rossdale to investigate the role of the micro-biome in people with Pulmonary Hypertension as a frequently fatal complication of Systemic Sclerosis, to help predict those who are more at risk of developing it, and to develop treatments
£20,000 to Dr Fiona Gillison to research best practice in digital technology delivery of patient care in rheumatology, on the experience during the COVID-19 pandemic to maximise virtual consultations

During the year, BIRD’s research grant programme was evaluated by Ben Hutchinson, member of the Research Committee, analysing the success of all grant making activity from 2016 to 2020. It was based on findings from interviews with grant recipients, Research Committee members, consultant trustees, and BIRD staff.

BIRD funding has supported clinicians from Rheumatology, Cardiology, Radiology, Respiratory, and Pulmonary Hypertension at the RUH, and in other leading centres including Leeds Children’s Hospital, and Alder Hey Children’s Hospital, enabling them to build their research portfolios.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

537 patients have been involved in a meaningful way on BIRD-funded projects, including in the design stage and as participants.

BIRD has funded 18 projects since 2016: 11 pumppriming projects, 3 matched PhD studentships, 3 adding value to large grants; and a series of summer studentships.

BIRD has helped to advance medical science, with grants generating at least 20 academic publications so far.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

Areas in which BIRD can increase its outputs, outcomes and impact, were outlined as recommendations which the Research Committee has taken responsibility for taking forward.

BIRD’s education programme for Healthcare Professionals

BIRD organises a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal National Hospital for Rheumatic Diseases, (based at the Royal United Hospital, Bath) the University of Bath and the Bath GP Education & Research Trust. BIRD provided the administration, support, including the accreditation and sponsorship where necessary, for educational events reaching 254 healthcare professionals.

Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

The Primary Care Rheumatology Update was held online on 6th October 2020 instead of in person.

New Rheumatology Research group meetings were instituted to bring together researchers at the University and clinicians at the hospital and to update one another on two new projects at a time. These were scheduled quarterly and very well attended and received.

All meetings ran successfully with higher numbers of attendees on average than face to face meetings with 254 attendees in total during this financial year. In 2019/20, 300 healthcare professionals attended. However, two meetings, the Bath and Bristol Weston Axial Spondyloarthritis meeting and the Bath and Bristol Bone meeting were postponed in Autumn 2020 due to the pandemic. It is envisaged that a combination of face to face and virtual meetings will be organised in future.

Dr Andrew Allard, consultant rheumatologist, joined the Education and Engagement committee to help shape the Education Programme with Senior Administrator Fran Staples.

----- Start of picture text -----
?
----- End of picture text -----

The Patient and Public Engagement Programme

This year, BIRD was unable to secure sponsorship for the education programme due to covid restrictions and compliance with pharmaceutical companies’ internal policies regarding virtual meetings. BIRD hopes to resume securing funding for future face to face events when possible.The South West CTD Vasculitis Group Meeting was held online on 15th September 2020 and 16th March 2021 instead of in person.

The vision is ‘to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment’. Phase two of the programme commenced in October 2020, to reach a wider spectrum of the population and for 85% of patient users to deepen their understanding and to encourage at least 150 more patients in research and build their confidence in participation. Specifically, this would be done

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

through creating a library of podcasts across nine rheumatic disease areas with over 2,000 listens, holding three live events with at least 200 attendees in total, growing the database to 600 patients, promoting research opportunities, producing three patient case studies, setting up a patient research panel, providing support to researchers for at least six focus groups or workshops, issuing at least eight surveys.

To the end of March 2021, 6 rheumatic disease areas had been covered (Scleroderma, Axial Spondyloarthritis, Young Adults, Vasculitis, Osteoporosis and Myositis) by 20 podcasts and an impressive 5,228 listens. The database stood at 533. Eight research opportunities had been promoted and researchers advised. A virtual workshop was held on the theme of ‘Coping with a rheumatic condition during the Coronavirus lockdown’.

Awareness Raising

The reach of BIRD was expanded exponentially through the investment in Facebook advertising for the podcasts, with over 200,000 people getting the opportunity to see a BIRD advertisement for the podcasts. Reactions (likes and comments) led to an invitation to like the BIRD Facebook page and encouragement to sign up to the e-newsletter database. The database is segmented into patients’ interest by disease area and stakeholders.

called ‘Ascending’ and was sculpted by skilled stonemason Steve Hall from natural Bath stone. A brass plaque also thanking donors was installed in the RNHRD waiting room.

Dr Ben Mulhearn, Rheumatology Clinical Academic Trainee, started training for running the Palma half marathon in October 2021 to raise funds for BIRD. He said: “With family links to rheumatoid arthritis and working in the field (as well as having a dodgy knee), this is my way to both raise money for rheumatology research and raise awareness of the discipline of rheumatology, as well as having a great time while doing so”. By the end of March, he had already raised £672.

Particular effort was spent in seeking to attract grants from Pharma companies for the Patient Engagement programme and resulting in one new company supporting it. However, the significant success of the reach of the podcast programme was not evident until after that round of applications, and the track record of attracting thousands of listeners may yet prove attractive to further sponsorship.

Grants were awarded to the Patient and Public

Engagement programme by the Champniss Charitable Trust, The Sperring Charity, HealthWatch, Eli Lilly and Company Ltd and UCB (the latter negotiated and agreed but will show in the following year’s accounts).

A new general leaflet and a 90 second animation of BIRD’s core purpose and recent results was produced in order to reach stakeholders on LinkedIn in particular.

A sculpted bird bath was craned into place outside the new Royal National Hospital for Rheumatic Diseases at the Royal United Hospital, on 10 September 2020. It is dedicated to the donors supporting Bath Institute for Rheumatic Diseases (BIRD) by funding scientific and clinical research since 1975 and marks the charity’s relocation to the hospital site. The artwork is

The main achievements and performance of the charity in terms of public benefit were:

The total amount of grants awarded for research into rheumatic diseases was £78,823.50
254 attendees at training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics
5,228 listens to podcasts for patients. The total

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

network reached via mailings and social media ad postings was estimated at almost 200,000 patients and members of the public. The investment in paid advertising promoted by a specialist agency explains this exponential increase

76% of listeners to podcasts understood their condition better as result
Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and Hospital
Fundraising continued to struggle at only £1,435 donations and £18,348 grants awarded, despite 75 grant applications written and a new emphasis on seeking pharma funding for the patient engagement programme. However, the latter was hampered by seeking pharma funding before the switch to podcasts had proved a demonstrable success in reaching so many people

Overall, the charity’s beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Group), chaired by Dr Nick Hall, members are Dr Lisa Austin, Professor Rod Flower, Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr John Pauling, Dr Sarah Skeoch, Frank Sweeting; and the quarterly Education & Engagement Committee (renamed in 2019 from the Patient Liaison and Fundraising Group), chaired by Stephanie Lear, members are Dr Andrew Allard, Judy Coles and Dr Patrick Ismond. All committees are supported by relevant contract staff in attendance.

Bankers:

Unity Trust Bank 9 Brindley Place, Birmingham B1 2HB

CCLA Investment Management Ltd COIF Charity Funds, Senator House, London

Royal London Asset Management 55 Gracechurch Street, London

Investec Wealth & Investment 30 Gresham Street, London EC2V 7QN

Solicitors:

Stone King 13 Queen Square, Bath BA1 2HJ

Accountants:

Structure, Governance and Management of the Charity

DR Hicks Chartered Accountants 107 Penn Hill Road, Bath BA1 3RU

The governing body is the Council of Management made up of 9 trustees. The chair is Chris Johns. Council of Management meets quarterly. Three committees report in to the Council of Management. These are the quarterly Finance Committee (renamed in 2019 from the Finance and Investment Group), chaired by Jim Sherwin, members are Dr Nick Hall, Dr Linda McHugh, Chris Johns and Linda Snelus; the biannual Research Committee (renamed in 2019 from the Research Assessment

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

Financial Review

The financial position of the charity at 31 March 2021 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:

Net income Unrestricted Revenue Funds available for the general purposes of the charity Designated Revenue Funds Total Unrestricted Funds Restricted Revenue Funds Total Funds	2021 £ 172,928 1,667,587 14,666 1,682,253 20,145 1,702,398	2020 £ (239,501)
		1,492,326 14,595
		1,506,921
		22,549
		1,529,470

The Finance Committee, on behalf of Council ensured BIRD’s investments maximised the funds available for furthering BIRD’s charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a ‘balanced’ return between income and capital, at medium risk over a time horizon of ten years plus.

BIRD’s Reserves Policy is to:

Hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies
Retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity’s assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time,

Both capital and income may be used at any time for the furtherance of the charity’s aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity’s reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2021 continued

Summary of plans for the future and the trustees’ perspective of the future direction of the charity

BIRD remains committed to funding research into rheumatic diseases at a level of £80,000 minimum. It will encourage thousands of patients to understand their disease better and hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

For the future, BIRD will be taking forward the first phase of recommendations from the research grant evaluation report. Specifically, in the next year, to:

Introduce a light touch process for capturing evidence of mid- to long term impact of its funding, capturing publications, follow on funding and real-world impact via email at 3- and 5-years post project
Continue to build on significant success in pumppriming research
Encourage proposals from allied health professionals
Run an annual or bi-annual conference for clinicians, researchers, allied health professionals, PhD students, patients, and other stakeholders

The Patient Engagement programme will continue to evolve and evaluate success, exploring new methods of virtual delivery if live events are not advisable. The third phase of the programme will be in development over the year ahead commencing late Spring 2022.

This year, the strong performance of investments meant that the gain on the value of investments was £304,942 resulting in a net income position for unrestricted funds of £175,332. The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. However, the achievements of the last few years in fundraising experiments remain modest. The experiment in bringing in specialist advice on pharma fundraising will continue another year to maximise opportunities from the increased numbers of patients reached through advertising podcasts, and a new trial of emphasis on legacy fundraising will take place over the next year.

Add a panel member with social sciences/ qualitative research expertise to the Research Committee
Explore novel ways of telling stories about funded research, for example, capturing testimonies of patients involved in research
Encourage patient co-authored papers, where appropriate

Details of The Independent Examiner

Mr Tom Case

Member of The Institute of Chartered Accountants in England and Wales

20 Goodwood Way Cepen Park South Chippenham Wiltshire SN14 0SY

Explore the availability of a space within the RUH to enable ‘hot-desking’ of academic researchers to facilitate research meetings between academic and clinical researchers

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of the Directors’ and Trustees’ Responsibilities

The charity’s trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business
State whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity’s transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

To prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law)
Select suitable accounting policies and apply them consistently

The Trustees are also responsible for the contents of the Trustees’ report, and the statutory responsibility of the Independent Examiner in relation to the Trustees’ report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Make judgements and estimates that are reasonable and prudent

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Method of preparation of accounts - Small Company Provisions

The financial statements are set out on pages 13-41.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016).

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 28 September 2021.

Christopher Johns, Chair

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2021

I report to the Trustees on my examination of the financial statements of the charitable company on pages 13 to 19 for the year ended 31 March 2021 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 22.

the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

A) Examine the financial statements of the charity under Section 145 of the Act

B) Follow the applicable procedures in the Directions given by the Charity Commission under section 145(5) (b) of the Act

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

Basis of independent examiner’s statement and scope of work undertaken

As described on page 9, you, the charitable company’s Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence,

I report in respect of my examination of the charity’s financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Report of the independent examiner to the trustees of the charitable company on the accounts for the year ended 31 March 2021 continued

Independent Examiner’s Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006

(as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable

Signed:

No material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

Mr Tom Case, Independent Examiner

The Institute of Chartered Accountants in England and Wales

Accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011
The financial statements do not accord with those records; or the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a ‘true and fair’ view, which is not a matter considered as part of an independent examination

20 Goodwood Way Cepen Park South Chippenham Wiltshire SN14 0SY

This report was signed on 28 September 2021.

Have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015,

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021

SORP Ref Income & Endowments from: Donations & Legacies A1 Charitable activities A2 Investments A4 Total income A Expenditure on: Charitable activities B2 Total expenditure B Net gains on investments B4 Net income for the year Transfers between funds C Net income after transfers A-B-C Net movement in funds Reconciliation of funds:- E Total funds brought forward Total funds carried forward	Current year Unrestricted Funds 2021 £ 20,340 22,449 49,315 92,104 223,799 223,799 304,942 173,247 2,085 175,332 175,332 1,506,921 1,682,253	Current year Restricted Funds 2021 £ - 615 - 615 934 934 - (319) (2,085) (2,404) (2,404) 22,549 20,145	Current year Total Funds 2021 £ 20,340 23,064 49,315 92,719 224,733 224,733 304,942 172,928 - 172,928 172,928 1,529,470 1,702,398	Prior Year Total Funds 2020 £ 12,731 47,602 62,591
				122,924
				255,462
				255,462
				(106,963)
				(239,501) -
				(239,501)
				(239,501) 1,768,971
				1,529,470

The ‘SORP Ref’ indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts. All activities derive from continuing operations

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021 continued

Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

SORP REF Income & Endowments from: Donations & Legacies A1 Charitable activities A2 Other trading activities A3 Investments A4 Other A5 Total income A Expenditure on: Raising funds B1 Charitable activities B2 Other B3 Tax on surplus on ordinary activity B3 Other taxation B3 Total expenditure B Net gains on investments B4 Net income for the year Transfers between funds C Net income after transfers Reconciliation of funds Reconciliation of funds:- E Total funds brought forward Total funds carried forward	Prior Year Unrestricted Funds 2020 £ 12,731 46,014 - 62,591 - 121,336 - 254,530 - - - 254,530 (106,963) (240,157) 1,616 (238,541) (238,541) 1,745,462 1,506,921	Prior Year Restricted Funds 2020 £ - 1,588 - - - (1,588) - 932 - - - 932 - 656 (1,616) (960) (960) 23,509 22,549	Prior Year Total Funds 2020 £ 12,731 47,602 - 62,591 -
			122,924
			- 255,462 - - -
			255,462
			(106,963) (239,501) -
			(239,501)
			(239,501)
			1,768,971
			1,529,470

All activities derive from continuing operations.

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021 continued

Statement of Total Recognised Gains and Losses for the year ended 31 March 2021

(Deficit)/Surplus for the year :- Net excess of income over expenditure from operations before tax Income from operations before tax in the Statement of Financial Activites Realised (losses)/gains on investments Surplus as shown in the Income and Expenditure account Unrealised (losses)/gains on investments Net Movement in funds before taxation Funds generated in the year as shown on Statement of Financial Activities	2021 £ (132,014) - (132,014) 16,967 (115,047) 287,975 172,928 172,928	2020 £ (132,538) -
		(132,538) (18,110)
		(150,648) (88,853)
		(239,501)
		(239,501)

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021 continued

Resources applied in the year ended 31 March 2021 towards fixed assets for Charity use

Funds generated in the year as detailed in the SOFA Resources applied on functional fixed assets Net resources available to fund charitable activities	2021 £ 172,928 (1,260) 171,668	2020 £ (239,501) (119)
		(239,620)

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021 continued

Movements in Revenue and Capital Funds for the Year Ended 31 March 2021

Revenue accumulated funds Accumulated funds brought forward Recognised gains and losses before transfers (From)/To unrestricted revenue funds Closing revenue funds	Unrestricted Funds 2021 £ 1,506,921 173,247 1,680,168 2,085 1,682,253	Restricted Funds 2021 £ 22,549 (319) 22,230 (2,085) 20,145	Total Funds 2021 £ 1,529,470 172,928 1,702,398 - 1,702,398	Last year Total Funds 2020 £ 1,768,971 (239,501)
				1,529,470 -
				1,529,470

Designated revenue funds included within the unrestricted funds above

unrestricted funds above
At 1 April Transfer (to)/from revenue accumulated funds At 31 March	Total Funds 2021 £ 14,595 71 14,666	Last year Total Funds 2020 £ 35,887 (21,292)
		14,595

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021 continued

Movements in Revenue and Capital Funds for the Year Ended 31 March 2021

Summary of funds

Revenue accumulated funds Revenue designated funds Total funds	Unrestricted and Designated Funds 2021 £ 1,667,587 14,666 1,682,253	Restricted Funds 2021 £ 20,145 - 20,145	Total Funds 2021 £ 1,687,732 14,666 1,702,398	Last Year Total Funds 2020 £ 1,514,875 14,595
				1,529,470

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of financial activities for the year ended 31 March 2021 continued

Income and Expenditure Account for the year ended 31 March 2021 as required by the Companies Act 2006

*Income* Income from operations Realised gains on investments Investment income Income from investments, other than interest receivable Gross income in the year before exceptional items	2021 £ 43,404 16,967 49,315 109,686 109,686 223,984 329 420 224,733 (115,047) - (115,047) (115,047)	2020 £ 60,333 (18,110) 62,591
		104,814

Gross income in the year including exceptional items		104,814
*Expenditure* Charitable expenditure, excluding depreciation and amortisation Depreciation and amortisation Governance costs Total expenditure in the year Net income before tax in the financial year Tax on surplus on ordinary activities Net income after tax in the financial year Retained surplus for the financial year		254,244 588 630
		255,462
		(150,648) -
		(150,648)
		(150,648)

All activities derive from continuing operations.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity’s activities.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Balance Sheet as at 31 March 2021

	Note	SORP Ref
				2021		2020
				£		£
Fixed assets		A
Tangible assets	10	A2		1,219		288
Investments held as fixed assets	11	A4		1,602,145		1,314,170
Total fixed assets				1,603,364		1,314,458
Current assets		B
Debtors	13	B2	9,798		11,281
Cash at bank and in hand		B4	259,598		460,491
Total current assets			269,396		471,772
Creditors: amounts falling due within one year	14	C1	(170,362)		(256,760)
Net current assets				99,034		215,012
The total net assets of the charity				1,702,398		1,529,470
The total net assets of the charity are funded by the funds of the		charity, as follows:-
Restricted funds
Restricted Revenue Funds	18	D2	20,145		22,549
				20,145		22,549
Unrestricted Funds
Unrestricted Revenue Funds	18	D3	1,667,587		1,492,326
				1,667,587		1,492,326
Designated Funds
Designated Revenue Funds	18	D3	14,666		14,595
				14,666		14,595
Total charity funds				1,702,398		1,529,470

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Balance Sheet as at 31 March 2021

The ‘SORP Ref’ indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 11.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

Mr JT Sherwin

Trustee and Chair of Finance Committee Approved by the board of trustees on 28 September 2021.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021

1. Accounting Policies Policies Relating to the Production of the Accounts

Policies relating to categories of income and income recognition

Basis of Preparation and Accounting Convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and ‘FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity’s jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Nature of Income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from nonexchange transactions (gifts), investment income and other income.

Income from exchange transactions is received

by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where

the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainites about the charity’s ability to continue as a going concern.

Income Recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Risks and Future Assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabiltities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Dividends are accrued when the shareholder’s right to receive payment is established.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from Legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Recognition of Liabilities and Expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities.

Policies relating to expenditure on goods and services provided to the charity.

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible Fixed Assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery - 20 % reducing balance.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes. Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law. There are no endowment funds.

2. Liability to Taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial Instruments Including Cash and Bank Balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

3. Winding up or Dissolution of the Charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4. Significance of Financial Instruments to the Charity’s Position

There are no significant implications of financial instruments to the charity’s financial position or performance.

5. Net Surplus Before Tax in the

Financial Year

The net surplus before tax in the financial year is stated after charging. Depreciation of owned fixed assets:

2021 = £329 2020 = £588

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

6. Investment Gains

*Current Year* *Realised gains/(losses)* Listed investments Total realised gains/(losses) *Unrealised gains /(losses) and writing down of* *carrying values* Listed investments - Unrealised Total unrealised gains/(losses) etc Total realised and unrealised gains	Current year Unrestricted Funds 2021 £ 16,967 16,967 287,975 287,975 304,942	Current year Restricted Funds 2021 £ - - - - -	Current year Total Funds 2021 £ 16,967 16,967 287,975 287,975 304,942	Prior Year Total Funds 2020 £ (18,110)
				(18,110)
				(88,853)
				(88,853)
				(106,963)

All gains and losses in the prior year was unrestricted.

Prior Year :-

*Realised gains/(losses)* Listed investments Total realised gains/(losses) *Unrealised gains /(losses) and writing down of carrying values* Listed investments - Unrealised Total unrealised gains/(losses) etc Total realised and unrealised gains	Prior Year Unrestricted Funds 2020 Prior Year Restricted Funds 2020 £ £ (18,110) - (18,110) - (88,853) - (88,853) - (106,963) -	Prior Year Total Funds 2020 £ (18,110)
		(18,110)
		(88,853) (88,853)
		(106,963)

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

7. Staff Costs and Emoluments

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

*Labour costs* Gross salaries, labour and related costs	2021 £ 111,081 111,081	2020 £ 113,458
		113,458

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8. Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

9. Trustees’ expenses

The expenses reimbursed to trustees, or paid directly to third parties, in the current or prior year, was as shown below.

The amount reimbursed to trustees:

2021 = nil

2020 = £228

The nature of the trustees’ expenses in 2020 was for travel expenses.

The number of trustees’ in 2020 to whom expenses were reimbursed was 1.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

10. Tangible Fixed Assets

*Current Year* Cost At 1 April 2020 Additions At 31 March 2021 Depreciation At 1 April 2020 Charge for the year At 31 March 2021 Net book value At 31 March 2021 At 31 March 2020	Land and Buildings £ - - - - - - -	Plant & Machinery £ 10,680 1,260 11,940 10,392 329 10,721 1,219 288	Motor Vehicles £ - - - - - - -	Total £ 10,680 1,260
				11,940
				10,392 329
				10,721
				1,219
				288

11. Investments Held as Fixed Assets

Carrying values of investments At 1 April 2020 Revaluation at 31 March 2021 At 31 March 2021 Analysis between fair value and historical cost Investments as above held at fair value	Investments in subsidiaries £ 2 - 2 2	Listed investments £ 1,314,168 287,975 1,602,143 1,602,143	Other Classes of Investment £ - - - -	Total £ 1,314,170 287,975
				1,602,145
				1,602,145

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

12. Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company’s investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary’s activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the six years ending 31st March 2021.

A summary of the unaudited financial statements of the subsidiary is :-

*Assets and Funds* Aggregate amount of assets Aggregate amounts of liabilities Aggregate amount of funds *Profit and Loss* *Net profit for the year before tax* *Net profit for the year after tax and Gift Aid* Funds retained within charitable subsidiaries The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	2021 £ (231) (316) (547) - - 2021 £ -	2020 £ (231) (316)
		(547)

		-
		-
		2020 £ -

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

13. Debtors

Trade debtors Prepayments and accrued income	2021 £ 6,851 2,947 9,798	2020 £ 4,846 6,435
		11,281

14. Creditors: Amounts Falling Due Within One Year

Trade creditors Accruals Other creditors	2021 £ 29,859 600 139,903 170,362	2020 £ 13,021 5,829 237,910
		256,760

15. Income and Expenditure account summary

At 1 April 2020 Surplus after tax for the year At 31 March 2021	2021 £ 1,618,323 (115,047) 1,503,276	2020 £ 1,768,971 (150,648)
		1,618,323

16. No related party transactions

There were no transactions with related parties in the year.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

17. Particulars of How Particular Funds are Represented by Assets and Liabilities

At 31 March 2021 Tangible Fixed Assets Investments at valuation:- Fixed asset investments Current Assets Current Liabilities At 1 April 2020 Tangible Fixed Assets Investments at valuation:- Fixed asset investments Current Assets Current Liabilities	Unrestricted funds £ 1,219 1,602,145 234,585 (170,362) 1,667,587 Unrestricted funds £ 288 1,314,170 434,628 (256,760) 1,492,326	Designated funds £ - - 14,666 - 14,666 Designated funds £ - - 14,595 - 14,595	Restricted funds £ - - 20,145 - 20,145 Restricted funds £ - - 22,549 - 22,549	Total funds £ 1,219 1,602,145 269,396 (170,362)
				1,702,398
				Total funds £ 288 1,314,170 471,772 (256,760)
				1,529,470

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

18. Change in Total Funds Over The Year as Shown in Note 17, Analysed By Individual Funds

*Unrestricted and designated funds:-* Unrestricted Revenue Funds Designated Revenue Funds Total unrestricted and designated funds *Restricted funds:-* Restricted - CRPS Conference Restricted - CRPS Network UK Restricted - Bone and Joint Restricted - Non comm trials Restricted - Arthritis Grand Challenge Restricted - Metabolic Bone Disease Total restricted funds Total charity funds	Funds brought forward from 2020 £ 1,492,326 14,595 1,506,921 1,121 2,085 14,145 2,085 67 3,046 22,549 1,529,470	Movement in funds in 2021 See Note 19 £ 173,247 - 173,247 - (394) - - - 75 (319) 172,928	Transfers between funds in 2021 See Note 20 £ 2,014 71 2,085 - - - (2,085) - - (2,085) -	Funds carried forward to 2022 £ 1,667,587 14,666
				1,682,253
				1,121 1,691 14,145 - 67 3,121
				20,145
				1,702,398

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

19. Analysis of Movements in Funds Over the Year as Shown in Note 18

*Unrestricted and designated funds:-* Unrestricted Revenue Funds *Restricted funds:-* Restricted - CRPS Network UK Restricted - Metabolic Bone Disease	Income 2021 £ 92,104 540 75 92,719	Expenditure 2021 £ (223,799) (934) - (224,733)	Other Gains & Losses 2021 £ 304,942 - - 304,942	Movement in funds 2021 £ 173,247 (394) 75
				172,928

20. Details of Transfers Between Funds

*The transfers shown in note 18 above are:-* To/(from) Unrestricted Revenue Funds in accordance with the accounting policy ‘Accounting for capital grants and fixed asset funds’. To/(from) Designated Revenue Funds To/(from) Restricted Revenue Funds Net transfers	2021 £ 2,014 71 (2,085)
	-

21. The Purposes of which the Funds:

Designated Revenue Funds Funds specific for this purpose.

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Restricted Revenue Funds Funds specific for this purpose.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the accounts for the year ending 31 March 2021 continued

22. Ultimate controlling party

The charity is under the control of its legal members. Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement